MiR-10a-5p targets TFAP2C to promote gemcitabine resistance in pancreatic ductal adenocarcinoma

机译：MiR-10a-5p靶向TFAP2C促进胰腺导管腺癌的吉西他滨耐药

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
引文网络
相似文献
相关主题

摘要

BackgroundBy regulating target genes, microRNAs play essential roles in carcinogenesis and drug resistance in human pancreatic ductal adenocarcinoma (PDAC). Previous studies have shown that microRNA-10a-5p (miR-10a-5p) is overexpressed in PDAC and acts as an oncogene to promote the metastatic behavior of PDAC cells. However, the role of miR-10a-5p in PDAC chemoresistance remains unclear.

机译：背景技术通过调节靶基因，microRNA在人类胰腺导管腺癌（PDAC）的致癌性和耐药性中起重要作用。先前的研究表明，microRNA-10a-5p（miR-10a-5p）在PDAC中过表达，并作为致癌基因促进PDAC细胞的转移行为。但是，miR-10a-5p在PDAC化学抗性中的作用仍不清楚。

著录项

期刊名称 Journal of Experimental Clinical Cancer Research : CR
作者
Guangbing Xiong; Hua Huang; Mengyu Feng; Gang Yang; Suli Zheng; Lei You; Lianfang Zheng; Ya Hu; Taiping Zhang; Yupei Zhao;
展开▼
作者单位

展开▼
年(卷),期 2018(37),-1
年度 2018
页码 76
总页数 15
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词
miR-10a-5p TFAP2C PDAC Chemoresistance Prognosis;

机译：miR-10a-5p;TFAP2C;PDAC;化学耐药性;预后;

相似文献

外文文献
中文文献
专利

1. MiR-10a-5p targets TFAP2C to promote gemcitabine resistance in pancreatic ductal adenocarcinoma [J] . Guangbing Xiong, Hua Huang, Mengyu Feng, Journal of experimental & clinical cancer research : . 2018,第1期

机译：MiR-10a-5p靶向TFAP2C以促进胰腺导管腺癌的吉西他滨耐药
2. LAMC2 promotes cancer progression and gemcitabine resistance through modulation of EMT and ATP-binding cassette transporters in pancreatic ductal adenocarcinoma [J] . Okada Yasuyuki, Takahashi Naoki, Takayama Tetsuji, Carcinogenesis . 2021,第4期

机译：LAMC2通过在胰腺导管腺癌中调节EMT和ATP结合盒式磁带转运蛋白来促进癌症进展和吉西他滨抗性
3. MicroRNA-155 Controls Exosome Synthesis and Promotes Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma [J] . Manabu Mikamori, Daisaku Yamada, Hidetoshi Eguchi, Scientific reports. . 2017,第1期

机译：MicroRNA-155控制外来的合成，促进胰腺导管腺癌中的吉西他滨抗性
4. Dual Targeting of NRP1 and EGFR Overcomes Resistance to Cetuximab in Pancreatic Ductal Adenocarcinoma with Intergrin Beta-1 Driven Src-Akt Bypass Signaling [C] . Du-San Baek, Ye-Jin Kim, Keunok Jung, PEGS . 2016

机译：NRP1和EGFR的双重靶向克服胰腺导管腺癌中胰腺导管腺癌的抗性，具有晶体β-1驱动的SRC-AKT旁路信号
5. ST6Gal-I Mediated Sialylation Promotes Pancreatic Ductal Adenocarcinoma Progression and Chemoresistance [D] . Chakraborty, Asmi. 2019

机译：ST6GAL-I介导的唾液酸化促进胰腺导管腺癌进展和化学性
6. MicroRNA-155 Controls Exosome Synthesis and Promotes Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma [O] . Manabu Mikamori, Daisaku Yamada, Hidetoshi Eguchi, -1

机译：MicroRNA-155控制外泌体合成并促进胰腺导管腺癌的吉西他滨耐药。
7. MiR-10a-5p targets TFAP2C to promote gemcitabine resistance in pancreatic ductal adenocarcinoma [O] . Guangbing Xiong, Hua Huang, Mengyu Feng, 2018

机译：MiR-10A-5P靶向TFAP2C，促进牙型血管腺癌腺癌抗性

MiR-10a-5p targets TFAP2C to promote gemcitabine resistance in pancreatic ductal adenocarcinoma

摘要

著录项

引文网络

相似文献

相关主题

期刊订阅